Abonements par 2 €

Par 2 € nodrošiniet

Institutional-grade intelligence for professional investors

LIVE

•Real-time feeds•Global markets•24/7 coverage

Sangamo Therapeutics Aktie News & Pressemeldungen

Sangamo Therapeutics Eulerpool Ziņas

14.10.2024. 15:53:23

Pfizer avanciert mit bahnbrechender FDA-Zulassung für Hämophilie-Medikament

20.12.2024. 15:07:52

Astellas und Sangamo schließen bahnbrechendes Lizenzabkommen zur Behandlung neurologischer Erkrankungen

31.12.2024. 00:50:40

Dramatischer Kurseinbruch bei Sangamo Therapeutics: Pfizer beendet Partnerschaft

31.12.2024. 01:32:22

Pfizer zieht sich zurück: Sangamo Therapeutics sucht neue Wege in der Gentherapie

31.12.2024. 04:28:20

Sangamo Therapeutics: Innovationsschmiede in der Genommedizin

1

2

1

2

Sangamo Therapeutics Akciju Ziņas

Sangamo Therapeutics tiek uzmanīgi vēroti no žurnālistu un investoru puses visā pasaulē. Jaunākās Sangamo Therapeutics ziņas mēs apkopojam šeit.

3. jūlijs ·
Yahoo
H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data
24. jūnijs ·
Yahoo
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
13. maijs ·
Yahoo
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
12. maijs ·
SeekingAlpha
Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript
12. maijs ·
Yahoo
Sangamo: Q1 Earnings Snapshot
28. aprīlis ·
Yahoo
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
4. aprīlis ·
SeekingAlpha
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
3. aprīlis ·
Yahoo
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
17. marts ·
SeekingAlpha
Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript
17. marts ·
SeekingAlpha
Sangamo Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation

1

2

1

2

Sangamo Therapeutics akciju preses relīzes

Sangamo Therapeutics regulāri publicē uzņēmuma tīmekļa vietnē ziņojumus, kas ir svarīgi investoriem.

Professional-grade financial intelligence

20M+ securities. Real-time data. Institutional insights.

Par 2 € nodrošiniet

Trusted by professionals at Goldman Sachs, BlackRock, and JPMorgan